New mRNA vaccine could reduce the recurrence and spread of skin cancer

Live updates

1. 23d ago

   Moderna and Merck mRNA vaccine clears phase 3 trials for melanoma

   A personalized mRNA vaccine combined with the immunotherapy drug pembrolizumab significantly reduced the risk of melanoma recurrence and spread in high-risk patients. Moderna and Merck announced the results this week, confirming the treatment successfully cleared phase 3 clinical trials. This neoantigen treatment instructs cells to produce proteins tailored to individual tumors to prevent the cancer from returning. The trial results move the vaccine to the final step before it can seek approval from the FDA.

   Why it matters

   Previous reports established the promise of mRNA vaccines in oncology. This specific approach uses genetic material to target unique tumor proteins. Success in this trial suggests a shift toward personalized cancer treatments.

   What is confirmed

   • Moderna and Merck developed a personalized mRNA vaccine that reduces melanoma recurrence.
   • The vaccine is used in combination with the immunotherapy drug pembrolizumab.
   • The treatment successfully cleared phase 3 clinical trials.
   • The vaccine targets neoantigens tailored to individual tumors.

   What to watch next

   • FDA approval decision
   • Results from broader patient demographics
   Sources used for this update (4)

   1. www.nationalgeographic.com — Why Scientists Say This Personalized Cancer Vaccine Could Be a Game-Changer
   2. www.smithsonianmag.com — A New Personalized Cancer Vaccine Could Keep Skin Cancer From Coming Back, Drugmakers Say
   3. www.medicalnewstoday.com — Novel mRNA vaccine plus immunotherapy reduces melanoma relapse in phase 3 trial
   4. medicalxpress.com — Personalized vaccine helped melanoma patients stay cancer-free longer, drugmakers say
   confidence 100%
2. 26d ago

   Moderna's mRNA vaccine shows promise in reducing skin cancer recurrence

   Moderna's experimental mRNA vaccine, in combination with Merck's cancer drug Keytruda, has shown promise in reducing the recurrence and spread of skin cancer, according to recent trial results. The vaccine, which uses a piece of genetic material called messenger RNA to instruct cells to produce a specific protein, has been found to be effective in reducing the risk of skin cancer recurrence. The results have sparked optimism about the potential for mRNA vaccines to be used in the treatment and prevention of cancer.

   Why it matters

   The development of mRNA vaccines has been a significant advancement in the field of immunotherapy, with the technology having been used to develop vaccines for COVID-19. The use of mRNA vaccines in cancer treatment is a relatively new area of research, but early results have been promising. Skin cancer is one of the most common types of cancer worldwide, and current treatments have varying degrees of success.

   What is confirmed

   • Moderna's mRNA vaccine, in combination with Merck's Keytruda, reduced skin cancer recurrence.
   • The vaccine uses messenger RNA to instruct cells to produce a specific protein.

   What to watch next

   • Further trial results
   • FDA approval
   • Commercial availability
   Sources used for this update (5)

   1. Bloomberg.com — Moderna’s 160% Surge Burns Shorts in ‘Painful’ $5 Billion Loss
   2. Reuters — Moderna, Merck breakthrough could usher in wave of cancer vaccines
   3. NPR — New mRNA vaccine could reduce the recurrence and spread of skin cancer
   4. The New York Times — From Covid to Cancer: How Moderna’s Stock Jumped 177% in a Day
   5. The Boston Globe — What Moderna’s vaccine trial results might mean for the future of cancer care
   confidence 90%